论文部分内容阅读
Background: Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily,weekly, or monthly.This 1-year, randomized, double-blind,multicenter study assessed the efficacy and safety of a single,35-mg weekly risedronate oral dose compared with the 5-mg daily regimen in Chinese postmenopausal women with osteoporosis or osteopenia.